PL2115477T3 - Zastosowanie IGFBP-7 do oceny niewydolności serca - Google Patents
Zastosowanie IGFBP-7 do oceny niewydolności sercaInfo
- Publication number
- PL2115477T3 PL2115477T3 PL08707286T PL08707286T PL2115477T3 PL 2115477 T3 PL2115477 T3 PL 2115477T3 PL 08707286 T PL08707286 T PL 08707286T PL 08707286 T PL08707286 T PL 08707286T PL 2115477 T3 PL2115477 T3 PL 2115477T3
- Authority
- PL
- Poland
- Prior art keywords
- igfbp
- assessment
- heart failure
- heart
- failure
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title 1
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4745—Insulin-like growth factor binding protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07001582 | 2007-01-25 | ||
| PCT/EP2008/000576 WO2008089994A1 (en) | 2007-01-25 | 2008-01-25 | Use of igfbp-7 in the assessment of heart failure |
| EP08707286.4A EP2115477B1 (en) | 2007-01-25 | 2008-01-25 | Use of igfbp-7 in the assessment of heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2115477T3 true PL2115477T3 (pl) | 2015-12-31 |
Family
ID=37810309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08707286T PL2115477T3 (pl) | 2007-01-25 | 2008-01-25 | Zastosowanie IGFBP-7 do oceny niewydolności serca |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20100285491A1 (pl) |
| EP (2) | EP2498095A3 (pl) |
| JP (1) | JP2010517023A (pl) |
| CN (2) | CN106908603B (pl) |
| CA (1) | CA2671298C (pl) |
| DK (1) | DK2115477T3 (pl) |
| ES (1) | ES2548009T3 (pl) |
| HU (1) | HUE025408T2 (pl) |
| PL (1) | PL2115477T3 (pl) |
| WO (1) | WO2008089994A1 (pl) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2498095A3 (en) * | 2007-01-25 | 2012-11-28 | Roche Diagniostics GmbH | Use of IGFBP-7 in the assessment of heart failure |
| WO2010096713A2 (en) * | 2009-02-20 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for the diagnosis of age-associated vascular disorders |
| WO2011012268A1 (en) * | 2009-07-27 | 2011-02-03 | Roche Diagnostics Gmbh | Use of mimecan in the assessment of heart failure |
| CN102792161B (zh) * | 2009-08-28 | 2014-11-12 | 阿斯图特医药公司 | 肾损伤和肾衰竭的诊断及预后的方法及组合物 |
| CN102725636B (zh) * | 2009-12-20 | 2015-04-01 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| CA2788826C (en) | 2010-02-05 | 2023-09-26 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2609427B1 (en) * | 2010-08-26 | 2015-01-21 | Roche Diagnostics GmbH | Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure |
| FI20115367A0 (fi) * | 2011-04-15 | 2011-04-15 | Hytest Oy | Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja |
| WO2013053076A1 (en) * | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| CN105785053B (zh) | 2011-10-17 | 2018-09-21 | 霍夫曼-拉罗奇有限公司 | 风险患者和中风原因的基于肌钙蛋白和bnp的诊断 |
| WO2013086359A1 (en) | 2011-12-08 | 2013-06-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2883057B1 (en) * | 2012-08-09 | 2018-12-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Diagnostic of heart failure |
| ES2680149T3 (es) | 2012-09-12 | 2018-09-04 | F. Hoffmann-La Roche Ag | Identificación de pacientes con fracción de acortamiento anormal |
| EP2730923A1 (en) * | 2012-11-09 | 2014-05-14 | Roche Diagniostics GmbH | NTproBNP and cTnT based therapy guidance in heart failure |
| CN113759128A (zh) * | 2012-12-04 | 2021-12-07 | 霍夫曼-拉罗奇有限公司 | 心力衰竭疗法的选择中的生物标记物 |
| JP6681195B2 (ja) | 2013-01-17 | 2020-04-15 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| PT3004891T (pt) | 2013-06-06 | 2019-05-30 | Inst Nat Sante Rech Med | Biomarcador de re-hospitalização após uma insuficiência cardíaca |
| EP2843414B1 (en) * | 2013-08-26 | 2018-09-19 | Roche Diagniostics GmbH | Marker for statin treatment stratification in heart failure |
| US9822172B2 (en) * | 2013-11-06 | 2017-11-21 | Astute Medical, Inc. | Assays for IGFBP7 having improved performance in biological samples |
| CN110007084B (zh) | 2013-12-03 | 2022-11-18 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
| ES2712201T3 (es) | 2014-01-28 | 2019-05-09 | Hoffmann La Roche | Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B |
| EP3413052B1 (en) * | 2014-03-26 | 2022-12-28 | Roche Diagnostics GmbH | Igfbp7 for diagnosing diastolic dysfunction |
| CN103926401A (zh) * | 2014-03-31 | 2014-07-16 | 瑞莱生物科技（江苏）有限公司 | 一种快速定量检测igfbp-7和timp-2的免疫荧光试纸条及其制备方法 |
| CN111407882A (zh) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| BR112017005554A2 (en) * | 2014-10-29 | 2018-01-23 | F. Hoffmann-La Roche Ag | methods for predicting a subject's risk of rapid progression to chronic heart failure and uses of at least one biomarker and at least one binding agent |
| CN104408717A (zh) * | 2014-11-24 | 2015-03-11 | 北京航空航天大学 | 一种基于着色分离的病理图像颜色质量综合评价方法 |
| US11243202B2 (en) | 2015-04-09 | 2022-02-08 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| KR20180117649A (ko) | 2016-02-29 | 2018-10-29 | 에프. 호프만-라 로슈 아게 | 자간전증의 마커로서의 igfbp-7 |
| CN109844526A (zh) | 2016-06-06 | 2019-06-04 | 机敏医药股份有限公司 | 使用胰岛素样生长因子结合蛋白7和金属蛋白酶2的组织抑制剂管理急性肾损伤 |
| BR112018073214A2 (pt) | 2016-06-17 | 2019-04-16 | F. Hoffmann-La Roche Ag | métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador |
| US10865412B2 (en) * | 2016-11-04 | 2020-12-15 | Ottawa Heart Institute Research | Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic diseases |
| KR102368403B1 (ko) | 2017-12-13 | 2022-02-25 | 에프. 호프만-라 로슈 아게 | 뇌졸중의 예측을 위한 순환하는 안지오포이에틴-2(Ang-2)와 인슐린-유사 성장 인자-결합 단백질 7(IGFBP7) |
| JP7557463B2 (ja) | 2018-07-20 | 2024-09-27 | エフ． ホフマン－ラ ロシュ アーゲー | Ｉｇｆｂｐ－７に基づく妊娠高血圧腎症の予測 |
| KR20210044216A (ko) | 2018-08-10 | 2021-04-22 | 에프. 호프만-라 로슈 아게 | 심방세동-관련 뇌졸중 평가를 위한 ces-2 (카르복실에스테라제-2) |
| EP3837549A1 (en) | 2018-08-16 | 2021-06-23 | Roche Diagnostics GmbH | Circulating tfpi-2 (tissue factor pathway inhibitor 2) in the assessment of atrial fibrillation and anticoagulation therapy |
| WO2020039001A1 (en) | 2018-08-22 | 2020-02-27 | Roche Diagnostics Gmbh | Circulating spon-1 (spondin-1) in the assessment of atrial fibrillation |
| EP3841382A1 (en) | 2018-08-24 | 2021-06-30 | Roche Diagnostics GmbH | Circulating fgfbp-1 (fibroblast growth factor-binding protein 1) in the assessment of atrial fibrillation and for the prediction of stroke |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| JP7399431B2 (ja) * | 2019-03-29 | 2023-12-18 | 栄研化学株式会社 | 動脈硬化及び動脈硬化関連疾患マーカー |
| CN113939741B (zh) | 2019-05-23 | 2025-07-22 | 豪夫迈·罗氏有限公司 | HFpEF的IGFBP7比率 |
| JP7625069B2 (ja) | 2020-08-14 | 2025-01-31 | エフ． ホフマン－ラ ロシュ アーゲー | 無症候性脳梗塞及び認知低下の評価のためのｉｇｆｂｐ７ |
| CN115957301A (zh) * | 2021-10-13 | 2023-04-14 | 中国科学院上海营养与健康研究所 | 一种促进心梗心肌修复的细胞分泌因子及应用 |
| EP4454663A4 (en) * | 2021-12-21 | 2026-04-08 | Univ Tokyo | THERAPEUTIC OR PROPHYLACTIC AGENT FOR HEART ATTACK, CARDIAC FIBROSIS OR HEART FAILURE, IN WHICH HTRA3 IS THE THERAPEUTIC TARGET |
| WO2023175152A1 (en) | 2022-03-18 | 2023-09-21 | Roche Diagnostics Gmbh | Troponin marker combinations for early discrimination of type 2 versus type 1 acute myocardial infarction |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174A (en) | 1849-03-13 | Improvement in balances for weighing | ||
| US686A (en) | 1838-04-13 | Machine foe faking- and goring | ||
| US6333397B1 (en) | 1989-04-25 | 2001-12-25 | Roche Diagnostics Gmbh | Monoclonal antibodies to troponin T and their production |
| DE3922873A1 (de) | 1989-04-25 | 1990-10-31 | Boehringer Mannheim Gmbh | Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen |
| JPH07132095A (ja) | 1993-06-11 | 1995-05-23 | Nawata Arata | Ｄｎａおよびそのコードする蛋白質 |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| ATE281648T1 (de) * | 1995-04-18 | 2004-11-15 | Biosite Diagnostics Inc | Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays |
| WO2000036105A1 (en) | 1998-12-18 | 2000-06-22 | Human Genome Sciences, Inc. | Prostacyclin-stimulating factor-2 |
| US6709855B1 (en) | 1998-12-18 | 2004-03-23 | Scios, Inc. | Methods for detection and use of differentially expressed genes in disease states |
| WO2000035473A2 (en) * | 1998-12-18 | 2000-06-22 | Scios Inc. | Methods for detection and use of differentially expressed genes in disease states |
| CA2356109C (en) * | 1999-01-06 | 2008-04-22 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
| AU758562B2 (en) * | 1999-01-29 | 2003-03-27 | Roche Diagnostics Gmbh | Method of identifying N-terminal proBNP |
| EP1295939A4 (en) | 2000-06-15 | 2005-02-02 | Kyowa Hakko Kogyo Kk | INSULIN SIMILAR GROWTH FACTOR BINDING PROTEIN |
| US20030119009A1 (en) * | 2001-02-23 | 2003-06-26 | Stuart Susan G. | Genes regulated by MYCN activation |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| JP3806694B2 (ja) | 2001-05-04 | 2006-08-09 | バイオサイト インコーポレイテッド | 急性冠状動脈症候群の診断マーカーおよびその使用方法 |
| GB0130557D0 (en) | 2001-12-20 | 2002-02-06 | Serono Internat S A | Proteins |
| WO2004042000A2 (en) | 2002-05-17 | 2004-05-21 | Human Genome Sciences, Inc. | 157 human secreted proteins |
| GB0216191D0 (en) * | 2002-07-11 | 2002-08-21 | Univ Leicester | Plasma urotensin in human heart failure |
| CA2522747C (en) | 2003-05-12 | 2012-08-14 | F. Hoffmann-La Roche Ag | Method of detecting native probnp with a monoclonal antibody binding to the amino acids 38-43 |
| GB0329288D0 (en) * | 2003-12-18 | 2004-01-21 | Inverness Medical Switzerland | Monitoring method and apparatus |
| US20060003338A1 (en) | 2004-06-30 | 2006-01-05 | Deng David X | System and methods for the management and treatment of vascular graft disease |
| US7659091B2 (en) * | 2004-09-21 | 2010-02-09 | Nourheart, Inc. | Diagnostic marker |
| ITVI20050059A1 (it) | 2005-03-04 | 2006-09-05 | Consorzio Per Gli Studi Universitari In Verona | Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali |
| WO2006123253A2 (en) * | 2005-03-29 | 2006-11-23 | Inverness Medical Switzerland Gmbh | Device and method of monitoring a patient |
| DE102005014752A1 (de) * | 2005-03-31 | 2006-11-23 | Johannes-Gutenberg-Universität Mainz | Entzündungsmarker und Kombinationen davon als biochemische Marker bei kardiovaskulären Erkrankungen |
| EP1722232A1 (en) * | 2005-05-09 | 2006-11-15 | F.Hoffmann-La Roche Ag | Devices and methods for diagnosing or predicting early stage cardiac dysfunctions |
| EP1731910A1 (en) * | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
| US7842472B2 (en) * | 2006-11-14 | 2010-11-30 | Alere International | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
| EP2498095A3 (en) * | 2007-01-25 | 2012-11-28 | Roche Diagniostics GmbH | Use of IGFBP-7 in the assessment of heart failure |
| ES2339284T3 (es) * | 2007-03-06 | 2010-05-18 | F. Hoffmann-La Roche Ag | Utilizacion de nogo-c en la deteccion de la insufuciencia cardiaca. |
| EP2145184B1 (en) * | 2007-03-08 | 2013-10-02 | Roche Diagnostics GmbH | Use of slim-1 in the assessment of heart failure |
| WO2011012268A1 (en) * | 2009-07-27 | 2011-02-03 | Roche Diagnostics Gmbh | Use of mimecan in the assessment of heart failure |
-
2008
- 2008-01-25 EP EP12156343A patent/EP2498095A3/en not_active Withdrawn
- 2008-01-25 HU HUE08707286A patent/HUE025408T2/hu unknown
- 2008-01-25 CN CN201610893998.1A patent/CN106908603B/zh active Active
- 2008-01-25 DK DK08707286.4T patent/DK2115477T3/en active
- 2008-01-25 PL PL08707286T patent/PL2115477T3/pl unknown
- 2008-01-25 WO PCT/EP2008/000576 patent/WO2008089994A1/en not_active Ceased
- 2008-01-25 JP JP2009546687A patent/JP2010517023A/ja active Pending
- 2008-01-25 ES ES08707286.4T patent/ES2548009T3/es active Active
- 2008-01-25 CA CA2671298A patent/CA2671298C/en active Active
- 2008-01-25 EP EP08707286.4A patent/EP2115477B1/en active Active
- 2008-01-25 CN CN200880003100A patent/CN101636656A/zh active Pending
-
2009
- 2009-07-16 US US12/504,208 patent/US20100285491A1/en not_active Abandoned
-
2014
- 2014-11-13 US US14/540,165 patent/US20150293122A1/en not_active Abandoned
-
2016
- 2016-10-05 US US15/285,685 patent/US10488422B2/en active Active
-
2019
- 2019-10-10 US US16/598,361 patent/US10996229B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106908603A (zh) | 2017-06-30 |
| EP2115477A1 (en) | 2009-11-11 |
| EP2115477B1 (en) | 2015-06-24 |
| CA2671298A1 (en) | 2008-07-31 |
| JP2010517023A (ja) | 2010-05-20 |
| WO2008089994A1 (en) | 2008-07-31 |
| CN106908603B (zh) | 2019-04-02 |
| EP2498095A2 (en) | 2012-09-12 |
| US20150293122A1 (en) | 2015-10-15 |
| US10996229B2 (en) | 2021-05-04 |
| US20100285491A1 (en) | 2010-11-11 |
| EP2498095A3 (en) | 2012-11-28 |
| ES2548009T3 (es) | 2015-10-13 |
| US20170016918A1 (en) | 2017-01-19 |
| US20200064359A1 (en) | 2020-02-27 |
| US10488422B2 (en) | 2019-11-26 |
| CA2671298C (en) | 2020-07-28 |
| DK2115477T3 (en) | 2015-08-10 |
| WO2008089994A8 (en) | 2009-05-22 |
| CN101636656A (zh) | 2010-01-27 |
| HUE025408T2 (hu) | 2016-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201007523B (en) | Heart age assessment | |
| IL212451A0 (en) | Adsorptive structures and the use thereof | |
| IL191773A0 (en) | Cardiac mechanical assessment using ultrasound | |
| GB0701426D0 (en) | Compounds and their use | |
| GB0803018D0 (en) | Therapeutic compounds and their use | |
| PL2036882T3 (pl) | Związki o jonach obojnaczych i ich zastosowanie | |
| PL2344449T3 (pl) | Związki arylo-fenylo-sulfonamido-cykloalkilowe i ich zastosowanie | |
| IL208081A (en) | Amido-Thiophene compounds and their use | |
| EP2171836A4 (en) | LAYER STRUCTURE CONNECTION AND ASSEMBLY | |
| ZA201007395B (en) | Aryl-quinolyl compounds and their use | |
| GB0817208D0 (en) | Therapeutic apsap compounds and their use | |
| EP2307052A4 (en) | ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE | |
| SI2496415T1 (sl) | Enostransko matirane folije in njihova uporaba | |
| IL212672A (en) | Cycloandesdepsipeptide compounds and their use in drug production | |
| GB0702022D0 (en) | Peptides and their use | |
| GB0812913D0 (en) | Therapeutic compounds and their use | |
| GB0708507D0 (en) | Substituted phosphonates and their use | |
| HU0700180V0 (en) | Loading area of the mattresses | |
| EP2252305A4 (en) | OMENTUM AND ITS USE | |
| EP2363132A4 (en) | USE OF SOPHORICOSIDE IN DRUG MANUFACTURE | |
| PT2182954T (pt) | Utilização de ácidos nor-biliares no tratamento de arteriosclerose | |
| GB0801319D0 (en) | Compounds and their use | |
| GB0703514D0 (en) | Use of riboflavin | |
| PL393311A1 (pl) | Elektroda wielowarstwowa i jej zastosowanie | |
| GB0802128D0 (en) | Therapeutic compounds and their use |